{"id":159539,"date":"2026-11-12T17:36:47","date_gmt":"2026-11-12T17:36:47","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/159539\/"},"modified":"2026-11-12T17:36:47","modified_gmt":"2026-11-12T17:36:47","slug":"the-heart-drug-pelacarsen-fails-shocking-novartis-and-cardiologists","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/159539\/","title":{"rendered":"The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists"},"content":{"rendered":"<p class=\"css-12m5bll evys1bk0\">Novartis announced on Friday that its experimental drug, pelacarsen, widely assumed to be the vanguard of a new era in preventing heart attacks, strokes and cardiovascular deaths, had <a class=\"css-povzk\" href=\"https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd\" title=\"\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">failed<\/a>.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The announcement gave no further details, but it came as a shock to the field of cardiology.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cOh no \u2014 oh no,\u201d said Dr. David Maron, president of the American Society for Preventive Cardiology. \u201cThis is a huge blow. I hardly know what to say.\u201d<\/p>\n<p class=\"css-12m5bll evys1bk0\">Dr. Harlan Krumholz, a Yale cardiologist, exclaimed: \u201cThis is extremely disappointing news. We\u2019ve all been looking forward to celebrating.\u201d<\/p>\n<p class=\"css-12m5bll evys1bk0\">The drug blocks a protein called lipoprotein (a) that is a powerful risk factor for heart disease. Every study short of a randomized clinical trial indicated that lowering Lp(a) would protect people from developing the disease.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Cardiologists widely expected that Lp(a) drugs would be the missing link in attempts to prevent heart attacks that can occur in people who do everything right \u2014 keep their cholesterol levels and blood pressure down, don\u2019t smoke, exercise and do not have obesity. Doctors held high hopes that the drugs could be as important as statins.<\/p>\n<p class=\"css-12m5bll evys1bk0\">\u201cHow much money has Novartis spent in the last two years promoting Lp(a) every which way?\u201d Dr. Krumholz said after expressing his complete disbelief.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Amgen and Eli Lilly have been pursuing similar drugs and conducting large clinical trials, raising questions about the entire enterprise.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The Novartis study lasted seven years and involved 8,323 people who had high Lp(a) levels and pre-existing heart disease. They injected the drug or a placebo once a month with a pre-filled syringe, much as obesity drugs are administered.<\/p>\n<p class=\"css-12m5bll evys1bk0\"><a class=\"css-povzk\" href=\"https:\/\/www.heart.org\/en\/health-topics\/cholesterol\/genetic-conditions\/lipoprotein-a\" title=\"\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">One in five people<\/a> have elevated Lp(a) levels. Worldwide, 1.4 billion to two billion people are affected.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The highest levels of Lp(a) \u2014 above <a class=\"css-povzk\" href=\"https:\/\/www.cdc.gov\/heart-disease-family-history\/about\/about-lipoprotein-a.html\" title=\"\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">50 milligrams per deciliter of blood<\/a>, found in 10 percent of the global population \u2014 are associated with a doubling of a person\u2019s risk of a heart attack or stroke. Even levels slightly higher than normal have an effect, increasing risk by 25 percent.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Yet unlike cholesterol, whose levels are affected by diet and obesity, there is no diet or lifestyle change that can affect Lp(a). It is determined by genes, and it does not fluctuate throughout life.<\/p>\n<p class=\"css-12m5bll evys1bk0\">In an earlier <a class=\"css-povzk\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40185318\/\" title=\"\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">study<\/a>, the Novartis drug reduced Lp(a) levels by 80 percent, making it seem a foregone conclusion that it would prevent heart attacks and strokes.<\/p>\n<p class=\"css-12m5bll evys1bk0\">For the clinical trial, Novartis simply reported the failure, complying with federal regulations requiring it to reveal results that could affect stock prices. The complete data set will be presented in November at the annual meeting of the American Heart Association, concurrently with a paper that will be published in a leading medical journal.<\/p>\n<p class=\"css-12m5bll evys1bk0\">There\u2019s a sobering lesson here, Dr. Krumholz said. All the studies finding strong evidence of an association are not proof of a cause and effect. It is always possible that what looks like a cause of heart disease is instead a marker, just as wrinkles are a marker of aging.<\/p>\n<p class=\"css-12m5bll evys1bk0\">Cardiologists have seen this sort of failure before: In August, they were shocked when a drug that reduces inflammation <a class=\"css-povzk\" href=\"https:\/\/www.nytimes.com\/2026\/08\/06\/science\/heart-disease-drug-fails-novo-nordisk.html\" title=\"\" rel=\"nofollow noopener\" target=\"_blank\">failed to protect<\/a> against heart disease.<\/p>\n<p class=\"css-12m5bll evys1bk0\">For years, cardiologists also thought that raising levels of HDL, the so-called good cholesterol, would protect people from heart disease. There was a promising drug, torcetrapib, that stunned people when it failed in a large clinical trial. (It actually increased risks.) High HDL levels were a marker, not a cause, of reduced risk.<\/p>\n<p class=\"css-12m5bll evys1bk0\">The C.E.O. of Pfizer, said Dr. Krumholz, \u201cthought the whole future of his company would be built on this drug.\u201d<\/p>\n<p class=\"css-12m5bll evys1bk0\">Two days before discovering the failure Pfizer had told the Food and Drug Administration it would be <a class=\"css-povzk\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1702474\/\" title=\"\" rel=\"noopener noreferrer nofollow\" target=\"_blank\">applying to market the drug<\/a>.<\/p>\n<p class=\"css-12m5bll evys1bk0\">But there still may be hope for the Lp(a) hypothesis. Maybe the other large clinical trials by Amgen and Lilly will find a benefit to lowering Lp(a).<\/p>\n<p class=\"css-12m5bll evys1bk0\">But, Dr. Krumholz added, \u201cThis leads you to question whether this is a fruitful area to continue on.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis announced on Friday that its experimental drug, pelacarsen, widely assumed to be the vanguard of a new&hellip;\n","protected":false},"author":2,"featured_media":159540,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[64939,1288,31056,23695,206,1078,61068,31107],"class_list":["post-159539","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-cholesterol","tag-clinical-trials","tag-drugs-pharmaceuticals","tag-heart","tag-novartis","tag-novartis-ag","tag-preventive-medicine","tag-stroke"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117604685368894906","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/159539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=159539"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/159539\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/159540"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=159539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=159539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=159539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}